- Home
- DRMA vs CNSP Comparison
DRMA vs CNSP Comparison
Compare DRMA & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- CNSP
- Stock Information
- Founded
- DRMA 2014
- CNSP 2017
- Country
- DRMA United States
- CNSP United States
- Employees
- DRMA N/A
- CNSP N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- CNSP Health Care
- Exchange
- DRMA Nasdaq
- CNSP Nasdaq
- Market Cap
- DRMA 3.5M
- CNSP 4.0M
- IPO Year
- DRMA 2021
- CNSP 2019
- Fundamental
- Price
- DRMA $5.48
- CNSP $6.48
- Analyst Decision
- DRMA Strong Buy
- CNSP Hold
- Analyst Count
- DRMA 1
- CNSP 1
- Target Price
- DRMA $10.00
- CNSP N/A
- AVG Volume (30 Days)
- DRMA 28.3K
- CNSP 80.0K
- Earning Date
- DRMA 08-13-2025
- CNSP 08-14-2025
- Dividend Yield
- DRMA N/A
- CNSP N/A
- EPS Growth
- DRMA N/A
- CNSP N/A
- EPS
- DRMA N/A
- CNSP N/A
- Revenue
- DRMA N/A
- CNSP N/A
- Revenue This Year
- DRMA N/A
- CNSP N/A
- Revenue Next Year
- DRMA N/A
- CNSP N/A
- P/E Ratio
- DRMA N/A
- CNSP N/A
- Revenue Growth
- DRMA N/A
- CNSP N/A
- 52 Week Low
- DRMA $5.09
- CNSP $4.93
- 52 Week High
- DRMA $24.90
- CNSP $221.94
- Technical
- Relative Strength Index (RSI)
- DRMA 37.22
- CNSP 43.40
- Support Level
- DRMA $5.09
- CNSP $4.93
- Resistance Level
- DRMA $6.09
- CNSP $7.32
- Average True Range (ATR)
- DRMA 0.52
- CNSP 0.93
- MACD
- DRMA -0.09
- CNSP 0.09
- Stochastic Oscillator
- DRMA 20.22
- CNSP 55.06
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.